Solarase

Solarase®

Dermatology A topical gel for treating actinic keratosis. See Actinic keratosis.
References in periodicals archive ?
The FDA approvable letter for Solarase and the completion of a European marketing agreement for Solarase, the pending re- launch of DepoCyt(R) by Chiron in quarter four and the successful European launch of Xatral OD by Sanofi-Synthelabo pave the way in our move towards profitability.
Lastly, the FDA approvable letter for Solarase and the completion of a European marketing agreement with Bioglan for Solarase, the pending re-launch of DepoCyt(R) by Chiron in quarter four and the successful European launch of Xatral OD by Sanofi-Synthelabo pave the way in our move towards profitability.
In March 2000, SkyePharma signed an agreement with Bioglan Pharma PLC for the manufacture, marketing and distribution of Solarase in Europe.
28 /PRNewswire/ -- SkyePharma PLC (Nasdaq: SKYE, LSE: SKP) announced today that it had acquired all the tangible assets and intellectual property of Hyal Pharmaceutical Corporation of Canada including the patents and rights to Solarase, Hyal's lead product, from the receiver of Hyal's assets pursuant to an Order of the Ontario Superior Court of Justice dated 25 October 1999.
SkyePharma would purchase the 12% subordinated debentures of Hyal for US$4,141,484 payable in ordinary shares of SkyePharma, with US$3,453,388 to be paid on closing and the balance of US$688,096 upon FDA approval of Solarase.
of Deerfield, Illinois, relating to the exclusive rights to license Solarase in the United States, Canada and Mexico.
We look forward to working together with the FDA in this review, which we hope will result in approval to market Solarase in the United States," said Dr.
Fujisawa") of Deerfield, Illinois, relating to the exclusive rights to license Solarase for the United States, Canada and Mexico.
Hyal believes that the up-front payments offered by Altana in connection with the license to Solarase will strengthen Hyal's financial position and enable Hyal to fund the continued development of promising product candidates''.
Solarase has been shown to be an effective topical therapy for actinic keratosis or sunspots, the forerunner of one of the most common forms of skin cancer - squamous cell carcinoma.
May 4 /CNW-PRN/ - Hyal Pharmaceutical Corporation (NASDAQ/NNM: HYALF; TSE: HPC) announced today that its lead product Solarase has received regulatory approval for marketing in Germany, Sweden, Italy and France, in addition to the previously announced approval for the United Kingdom.
Sam Asculai, CEO of Hyal, commented that, ``With the Hyanalgese-D Phase III trial results to be released shortly, as well as the possible market approval for Solarase in a number of countries, the next few months will be a time of great activity for Hyal.